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GATA3 somatic mutations are 
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The effect of somatic mutations and the gene expression profiles on the prognosis is well documented 
in cancer research. This study was conducted to evaluate the association of GATA3 somatic mutations 
with tumor features, survival, and expression profiles in breast cancer. Clinicopathological information 
was compared between TCGA-BRCA patients with GATA3-mutant and non-mutant tumors in 
all patients as well as in ER-positive subgroup. Cox-regression method was used to evaluate the 
association of the GATA3 mutation status with overall survival time. Differential gene expression, 
functional annotation, and protein–protein interaction analyses were performed using edgeR, 
Metascape, DAVID, STRING and CytoNCA. GATA3-mutant and non-mutant samples had significantly 
different clinicopathological features (p < 0.05). While GATA3 mutation status was not associated with 
the overall survival in the entire cohort (padj = 0.52), the GATA3-wild type ER-positive cases had a better 
prognosis than mutant ones (padj = 0.04). GATA3 expression was higher in tumors than normal tissues. 
Several pathways were different between mutant and non-mutant groups (p < 0.05). Interleukin-6 was 
found as the highest scored gene in both comparisons (normal vs. mutant and normal vs. non-mutant 
groups) in the entire patient and in the ER-positive subgroup, suggesting the association of IL6 with 
breast tumorigenesis. These findings suggest that GATA3 mutations can be associated with several 
tumor characteristics and influence the pattern of gene expression. However, GATA3 mutation status 
seems to be a prognostic factor for the disease only in ER-positive patients.
Breast cancer, the most common type of cancer in women worldwide, is a heterogeneous disease with dif-
ferent pathological and molecular features and  subtypes1. The disease is caused by both environmental and 
genetic  factors2. In this regard, numerous genetic risk factors have been identified for tumor development and 
 progression3. Except for the genes with highly penetrant and hereditary mutations, such as BRCA1 and BRCA24, 
the genetic basis of breast cancer and the role of genetic variations and their effects on malignant transforma-
tion are currently complex and requires further investigations. Several studies have demonstrated that somatic 
mutations in oncogenes and tumor suppressor genes are major drivers of different types of breast tumors and 
correlate with clinicopathological characteristics of the disease, response to therapy, or  prognosis5–7. GATA bind-
ing protein 3 (GATA3) is one of the important genes involved in breast cancer  development8.
GATA binding protein 3 is a transcription factor that encodes a protein member of the GATA family. GATA 
family members have two conserved Zinc-finger DNA binding domains. This transcription factor binds to 
promoters of target genes through the consensus (A/T)GATA(A/G)  motifs9. Previous studies have demon-
strated that GATA3 protein has crucial roles in cell development and differentiation in different types of cells, 
including mammary  tissue10. Therefore, variations in its expression can affect downstream pathways and result 
in changes in cellular characteristics as its higher expression has been identified in hormone receptor-positive 
breast cancer  patients11. While some data have pointed out that the GATA3 expression level is not an independent 
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prognostic  factor11, several researchers have reported that it was associated with better survival in breast cancer 
 patients12,13. Also, it has been reported that breast tumors expressing low levels of GATA3 were correlated with 
larger  tumors14. A literature report suggests that related pathways may be the reason for the association of this 
gene with some clinical features of breast  cancer15,16. In light of these findings, GATA3 has been considered as 
an important gene in breast development and  cancer17. However, the role of GATA3 somatic mutations in the 
development of breast tumor characteristics, patient survival outcomes, and its impact on tumor gene expression 
profiles is poorly understood.
In this study, we evaluated the genomic alterations of GATA3 in breast tumors, using the data collected by 
TCGA 18, and analyzed the associations of GATA3 somatic mutations with tumor features, patient survival, and 
tumor gene expression profiles to highlight the clinical importance of this gene in breast cancer.
Results
GATA3 somatic mutation status and association with clinicopathological features. In the 
TCGA-BRCA cohort, tumors of 975/1085 female patients were evaluated for somatic mutations. Among these 
patients, a total of 103 different GATA3 mutations were identified in 138 patients (14.15%). Insertions consti-
tuted the largest type of mutations (50.5%), followed by deletions (29.1%) and substitutions (20.4%). A large por-
tion of the mutations (74.7%) resulted in frame-shifts and variant effect predictor (VEP)19 has indicated 96.3% of 
all mutations were predicted to have a high or moderate impact. The most frequent mutation was X309, which 
is a two-base pairs (CA) deletion/splice site mutation (chr10:g.8069470delCA, annotated as GATA3 X309_splice 
in the GDC portal). This mutation was detected in tumors from 21 patients (15.22% of patients with GATA3 
mutations). There were 11 additional recurrent mutations identified in more than one patient (n = 2–8), while 
the rest of the mutations were detected only in one patient.
The average diagnosis age was 45.66 ± 13.65 and 58.77 ± 12.97 in patients with and without GATA3 muta-
tions, respectively (p = 0.001; Table 1). We compared the GATA3 mutation status in patients with different age 
categories. This analysis showed that the proportion of the patients with GATA3 mutated tumors was higher in 
the patients diagnosed under 40 years of age compared to those who were diagnosed after 40 years of age [20 of 
89 patients under 40 years old (22.5%) and 118 of 885 patients above 40 years old (13.3%), respectively; p = 0.02]. 
In addition to age at diagnosis, menopausal status was significantly different between patients with and without 
GATA3 mutations (p = 0.00004; Table 1). Other clinicopathological characteristics that were associated with 
GATA3 mutation status in this patient cohort (Table 1) are the following: pathologic tumor size was significantly 
different between patients with GATA3 mutant tumors compared to patients with wild-type GATA3 tumors 
(p = 0.01). A significant difference was also seen with tumor histological types. There was a strong relationship 
between the GATA3 mutation and ER/PR status; almost none of the tumors with GATA3 mutations were ER-
negative (Table 1). Additionally, in the multivariable logistic regression analysis, age at diagnosis, tumor size (pT), 
PR status, and histological tumor type were found to be independently associated factors of GATA3 mutation 
status in breast cancer (Table 2).
We repeated these analyses in the ER-positive subgroup (Tables 1, 2). Overall, the results in this subgroup 
analysis were similar to that of the entire patient cohort. An interesting finding in the ER-positive subgroup analy-
sis was that the mutant cases were more frequently presented than non-mutants in the Asian population (Table 1).
GATA3 somatic mutations and prognosis. The median overall survival was 10.80 ± 0.7  years 
(11.69 ± 3.63 and 10.61 ± 2.19 years in patients without GATA3 mutation compared with patients with GATA3 
mutation, respectively; p = 0.73). There was no significant difference between the two groups in terms of median 
survival time. This finding was also similar in the ER-positive subgroup (Table 3).
Univariate Cox proportional hazard analysis indicated age at diagnosis, menopause status, lymph node ratio, 
history of neoadjuvant therapy and adjuvant radiation therapy to be associated with survival times in the patients. 
Also, several tumor characteristics including margin status, pathologic tumor size (pT), lymph node (pN), and 
stage were associated with overall survival (Table S2).
While Multivariable Cox regression model adjusting for prognostic factors revealed that GATA3 somatic 
mutation status was not an independent prognostic factor for all patients (padj = 0.52), wild type samples indi-
cated better prognosis in the ER-positive subgroup (padj = 0.04) (Table 3). However, age (padj = 0.0001), stage 
(padj = 7.461E−10) and radiation therapy (p = 0.003) were significantly and independently associated with overall 
survival time in the entire patient cohort. Analysis of the ER-positive cases indicated age (padj = 2.411E−8) and 
stage (padj = 0.026) as independent factors associated with overall survival time.
Gene expression analysis. According to the TCGA expression data, GATA3 expression level was higher 
in GATA3-mutant (log FC = 2.78, p = 4.38E−34 in all patients and log FC = 2.66, p = 2.07E−57 in ER-positive 
subgroup) and non-mutant (log FC = 1.76, p = 2.11E−21 in all patients and log FC = 1.96, p = 3.24E−46 in ER-
positive subgroup) tumors than normal tissues. While mutant tumors had a higher level than non-mutants (log 
FC = 1.02; p = 1.15E−12), this was not detected in the analysis of the ER-positive breast cancer patients.
A total of 4816 differentially expressed genes (DEGs) were observed between the GATA3-mutant and nor-
mal tissues (2476 up-regulated and 2340 down-regulated genes). Additionally, there were a total of 4308 DEGs 
between the GATA3-non-mutant and normal tissues (2593 up-regulated and 1715 down-regulated genes). Finally, 
907 DEGs between the non-mutant and mutant tumors were found: 169 genes were up-regulated and 738 genes 
were down-regulated at an FDR < 0.05 and log fold change (log FC) > 1. In the ER-positive subgroup, 4522 (2143 
up-regulated and 2379 down-regulated genes), 4066 (2055 up-regulated and 2011 down-regulated genes) and 
480 genes (103 up-regulated and 377 down-regulated genes) were found in the comparison between mutant 
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Variables All patients ER-Positive patients
Categories Wild n (%) Mutant n (%) p  valuea  OR (95% CI) Wild n (%) Mutant n (%) p  valuea OR (95% CI)
Age
Mean 58.77 ± 12.97 45.66 ± 13.65 0.001 0.98 (0.96–0.99) 60.03 ± 13.02 54.81 ± 13.68 0.00005
0.09 
(0.95–0.98)
Age ≤ 35 25 (3%) 6 (4.3%) 16 (2.8) 5 (3.9)
Age > 35 811 (97%) 14 (95.7%) 0.40 0.68 (0.27–1.68) 565 (97.2) 123 (96.1) 0.489
1.43 
(0.52–3.99)
Age ≤ 40 69 (8.3%) 20 (14.5%) 39 (6.7) 19 (14.8)




Peri and Pre 193 (25.6%) 53 (43.8%) 123 (23.3) 49 (43.4%)




White 577 (75.8%) 95 (73.1%) 418 (81.2) 85 (70.8)
Black/African-
American 138 (18.1%) 22 (16.9%) 0.90
0.97 
(0.59–1.60) 75 (14.5) 22 (18.3) 0.175
1.44 
(0.85–2.45)
Asian 46 (6.1%) 13 (10%) 0.10 1.72 (0.89–3.30) 22 (4.3) 13 (10.8) 0.004
2.91  
(1.41–5.99)
History of other malignancy
No 783 (93.7%) 132 (95.7%) 537 (92.4) 122 (95.3)
Yes 53 (6.3%) 6 (4.3%) 0.37 0.67 (0.28–1.59) 44 (7.6) 6 (4.7) 0.253
0.60  
(0.25–1.44)
History of neoadjuvant therapy
No 826 (98.8%) 135 (98.5%) 572 (98.3) 125 (98.4)




Negative 698 (89.9%) 117 (88%) 482 (89.1) 108 (87.1)
Positive/Close 78 (10.1%) 16 (12%) 0.49 1.22 (0.69–2.17) 59 (10.9) 16 (12.9) 0.526
1.21  
(0.67–2.18)
Number of involved lymph node
Median (Q1–
Q3) 2.28 ± 4.46 1.95 ± 3.31 0.45
0.98 





Q3) 0.16 ± 0.26 0.18 ± 0.27 0.56
1.25 
(0.61–2.57) 0.06 (0.0–0.25) 0.06 (0.0–0.24) 0.756
0.88  
(0.39–1.98)
Lymph node ratio category
Negative = 0 349 (49.4%) 53 (46.5%) 218 (44.8) 48 (45.7)




(> 0.2–0.65) 118 (16.7%) 23 (20.2%) 0.36
1.28 
(0.75–2.19) 89 (18.3) 21 (20.0) 0.812
1.07  
(0.61–1.79)




T1 and T2 717 (85.9%) 106 (77.4%) 496 (85.4) 99 (78.0)




Negative 398 (48.4%) 62 (46.6%) 256 (44.8) 57 (46.0)




Negative 702 (97.2%) 115 (97.5%) 492 (98.6) 105 (97.2)




Stage 1 and 2 627 (76.7%) 96 (71.1%) 428 (75.1) 90 (72.0)
Stage 3 and 4 191 (23.3%) 39 (28.9) 0.16 1.33 (0.89–2.00) 142 (24.9) 35 (28.0) 0.473
1.17  
(0.76–1.81)
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versus normal, non-mutant versus normal and non-mutant versus mutant tumors, respectively. Volcano plots 
are shown in Fig. 1.
The most up and down-regulated DEGs in three categories of comparison are listed in Table 4. MYH2 and 
CKM in mutant versus normal and non-mutant versus normal and SMR3B in mutant versus non-mutant were 
the top down-regulated genes. The top up-regulated genes were MUC2, S100A7A and ALDOB in mutant versus 
Table 1.  Results of univariate logistic regression analysis examining the association between GATA3 mutation 
status and clinical features. AJCC American Joint Committee on Cancer, CI confidence interval, ER estrogen 
receptor, IDC invasive ductal carcinoma, IHC immunohistochemistry, ILC invasive lobular carcinoma, ISH 
in situ hybridization, OR odds ratio, PR progesterone receptor, TNBC triple negative breast cancer. a Significant 
p values are shown in bold. b According to ISH/IHC results.  cAssociation between the receptor status and 
GATA3 mutation status cannot be estimated because all GATA3 mutant tumors are also ER and/or PR positive. 
Significant p values are shown in bold.  dOther category includes rare types of tumors (e.g. Metaplastic, 
Medullary tumors).
Variables All patients ER-Positive patients
Categories Wild n (%) Mutant n (%) p  valuea  OR (95% CI) Wild n (%) Mutant n (%) p  valuea OR (95% CI)
Negative 216 (27.1%) 1 (0.8%) – – – –
Positive 582 (72.9%) 128 (99.2%) 0.0001 47.51 (6.60–341.94) – – – –
PR status by IHC
Negative 282 (35.5%) 24 (18.5%) 83 (14.3) 23 (18.0)




Negative 589 (81.5%) 91 (85%) 431 (81.6) 91 (85.0)




ER and/or PR 
positive 598 (77.3%) 129 (100%) – – – –
HER2 overex-
pressed 32 (4.1%) 0 (0%) 1.00 0.00 (–) – – – –
TNBC 144 (18.6%) 0 (0%) 1.00 0.00 (–) – – – –
Anatomic neoplasm subdivision
Left 432 (51.6%) 75 (54.3%) 299 (51.4) 69 (53.9)
Right 405 (48.4%) 63 (45.7%) 0.55 0.90 (0.62–1.29) 283 (48.6) 59 (46.1) 0.604
0.90  
(0.62–1.33)
Histological type of tumord
IDC 617 (73.8%) 103 (74.6%) 400 (68.7) 96 (75.0)
ILC 148 (17.7%) 14 (10.1%) 0.06 0.57 (0.32–1.02) 136 (23.4) 14 (10.9) 0.005
0.43  
(0.24–0.78)
Other 71 (8.5%) 21 (15.2%) 0.03 1.77 (1.04–3.01) 46 (7.9) 18 (14.1) 0.104
1.63  
(0.91–2.94)
Table 2.  Results of the multivariable logistic regression analysis. Significant p values are shown in bold. 
CI confidence interval, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, OR odds ratio, PR 
progesterone receptor. a Other category includes rare histological types, such as metaplastic and medullary 
tumors.
All patients ER-Positive patients
Variable p value OR (95% CI) Variable p value OR (95% CI)
Age at diagnosis 0.00040 0.97 (0.96–0.99) Age at diagnosis 0.001 0.97 (0.96–0.99)
Tumor size (T3 and T4 vs. T1 and T2) 0.00262 2.09 (1.29–3.38) Tumor size (T3 and T4 vs. T1 and T2) 0.195 1.45 (0.83–2.45)
Histological  typea 0.00513 Histological type
ILC versus IDC 0.00968 0.44 (0.23–0.82) ILC versus IDC 0.011 0.42 (0.21–0.81)
Other type versus IDC 0.12139 1.59 (0.88–2.86) Other type versus IDC 0.075 1.76 (0.94–3.30)
PR status (positive vs. negative) 0.00001 2.92 (1.81–4.73) Race
- - - Black/African American versus White 0.285 1.35 (0.78–2.34)
- - - Asian versus White 0.031 2.29 (1.08–4.86)
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normal, non-mutant versus normal and mutant versus non-mutant, respectively. The ER-positive subgroup 
analysis showed MUC2, CST5 and ALDOB as the top up-regulated genes and MYH2 as the top down-regulated 
gene between mutant versus normal, non-mutant versus normal, and CSN1S1 as the top down-regulated gene 
between mutants versus non-mutant samples.
Venn diagram shows the common and specific genes in every group. As it can be seen in Fig. 2, 389 and 236 
genes are common in the three groups of all and ER-positive patients, respectively, that might be involved in 
breast carcinogenesis and also be influenced by GATA3 mutations.
Functional annotation analysis of differentially expressed genes. To gain an insight into the func-
tionality of the DEGs between normal and tumor (mutant and non-mutant) samples, gene set enrichment analy-
sis was performed using the Metascape and DAVID functional enrichment tool. According to DAVID outputs, 
36 pathways found to be significantly different between GATA3-mutant and normal samples, 7 pathways had 
been previously reported as the most important pathways related to breast cancer (p ≤ 0.05)20–22. Evaluation of 
Table 3.  Results of the univariate and multivariable Cox regression analysis for GATA3 mutation status. CI 
confidence interval, HR hazards ratio.
Cox regression
All patients ER-Positive patients
Variable p value HR (95% CI) Variable p value HR (95% CI)
Univariate GATA3 mutation status (yes vs. no) 0.73 1.09 (0.66–1.80)
GATA3 mutation status 
(yes vs. no) 0.40 1.26 (0.74–2.15)
Multivariable
GATA3 mutation status 
(yes vs. no) 0.52 1.22 (0.66–2.26)
GATA3 mutation status 
(yes vs. no) 0.040 1.84 (1.03–3.27)
Age at diagnosis 0.0001 1.03 (1.02–1.05) Age at diagnosis 2.411E−8 1.05 (1.03–1.07)
Stage category (S3 and S4 
vs. S1 and S2) 7.461E−10 4.11 (2.62–6.44)
Stage category (S3 and S4 
vs. S1 and S2) 0.026 1.90 (1.09–3.33)
Radiation therapy status 
(yes vs. no) 0.003 0.49 (0.31–0.79)
Lymph node status 
category (positive vs. 
negative)
0.104 1.63 (0.90–2.96)
Figure 1.  Volcano plats showed analysis of differential expressed genes (DEGs) between the normal compared 
with the tumors (GATA3-mutant and non-mutant). (A)  Log2-fold change mutant and normal; (B) non-mutant 
and normal; (C) non-mutant and mutant; (D)  Log2-fold change mutant and normal in ER-positive patients; (E) 
non-mutant and normal in ER-positive patients; (F) non-mutant and mutant in ER-positive patients. Green dots 
represent significantly DEGs (FDR < 0.05 and log FC > 1).
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non-mutant tumors against normal tissue samples indicated 37 significantly different. Also, 3 different path-
ways (protein digestion and absorption; Wnt signalling; and cell adhesion molecules) were significantly different 
between mutant and non-mutant tumor tissues. Analysis of ER-positive patients indicated 37 and 36 signifi-
cantly different pathways in normal samples in comparison with mutant and non-mutant tumors, respectively. 
Furthermore, pancreatic secretion pathway was different between mutant and non-mutant tumors. These results 
are shown in the supplementary information file, Table S3.
PPI network of module analysis. To gain a better understanding of the biological relationships between 
breast cancer-related genes, the genes that share the same GO term related to breast cancer were examined in the 
STRING database. Results indicated that 116 and 95 genes (proteins) for all patients and 142 and 191 for ER-pos-
itive subgroup matched the database and were used to construct the PPI network between GATA3 mutant tumor 
and normal tissues (Fig. 3) and between GATA3 non-mutant tumor and normal tissues, respectively (Fig. 4). 
The top nodes with high topology score that were calculated by three centrality methods, were considered as 
hub nodes. Interleukin 6 (IL6) had the highest scores in three centrality methods in both comparisons between 
normal and mutant and normal and non-mutant groups in all patients as well as ER-positive subgroup. FN1, 
IGF1, FGF2 and LEP in all patients and, LEP and FN1 genes in the ER-positive subgroup could be considered as 
hub nodes in normal and mutant. Moreover, IGF1, FGF2, FN1 and SPP1 genes in all patients and FOS, FGFR, 
LEP and CDK1 genes in ER-positive subgroup could be considered as hub nodes in normal and non-mutant 
Table 4.  Differentially expressed genes (DEGs) between GATA3-mutant versus normal and GATA3-non-
mutant versus normal and GATA3-mutant versus non-mutant tissues according to the TCGA data.
Gene name Fold change FDR Gene name Fold change FDR
GATA3 mutant versus normal All patients: 4816 (2476 up-regulated and 2340 down-regulated genes)
ER-Positive patients: 4522 (2143 up-regulated and 2379 down-regu-
lated genes)
Up-regulated DEGs
MUC2 10.43879 3.33E−24 MUC2 8.329625376 2.62 E−18
CGA 9.492646 3.97 E−24 CHRNA9 7.628457572 7.85 E−21
CHRNA9 9.389171 1.25E−26 CGA 7.332730083 1.31E−18
CPLX2 8.522081 5.63E−19 PCSK1 6.922966106 1.79E−19
CST4 8.506592 2.09E−43 TRH 6.85432771 8.50E−19
Down-regulated DEGs
MYH2 − 11.8785 1.83E−45 MYH2 − 11.8811779 6.71E−38
CKM − 11.8163 3.02E−44 NRAP − 9.667105996 8.76E−31
NRAP − 9.63614 4.01E−36 TNNC2 − 8.329242401 9.99E−42
TNNC2 − 8.32733 3.04E−51 TCAP − 8.199816299 5.68E−32
ACTA1 − 8.21929 4.09E−35 ACTA1 − 8.118831848 4.32E−30
GATA3 non-mutant versus normal All patients: 4308 (2593 up-regulated and 1715 down-regulated genes)
ER-Positive patients: 4066 (2055 up-regulated and 2011 down-regu-
lated genes)
Up-regulated DEGs
S100A7A 8.467232 9.82E−22 CST5 6.658392275 1.67E−18
CSAG1 8.423582 3.50E−26 S100A7A 6.546948974 1.96E−16
CST5 8.403968 2.03E−22 CGA 6.525469762 1.16E−17
CGA 8.399469 2.10E−22 CARTPT 6.349247937 1.00E−10
MAGEA12 8.173768 5.55E−22 CST4 6.32237147 7.11E−34
Down-regulated DEGs
MYH2 − 8.18882 1.49E−120 MYH2 − 7.688190533 6.83E−80
CKM − 7.80643 4.34E−112 PYGM − 6.809240454 7.50E−145
PYGM − 7.07911 1.61E−215 ACTA1 − 6.782578399 4.19E−79
NRAP − 6.89436 1.09E−95 ATP2A1 − 6.539245722 2.40E−113
ATP2A1 − 6.75453 8.90E−171 NRAP − 6.423415223 1.04E−63
GATA3 mutant versus non-mutant All patients: 907 (169 up-regulated and 738 down-regulated genes) ER-Positive patients: 480 (103 up-regulated and 377 down-regulated genes)
Up-regulated DEGs
ALDOB 3.731806 9.25E−87 ALDOB 4.193275263 1.63E−90
AMY2A 3.414509 9.25E−87 AMY2A 3.62447513 3.97E−73
C8orf34 3.308972 2.16E−59 C8orf34 3.23103563 1.77E−44
ZPLD1 2.907425 4.75E−32 ZPLD1 2.950533096 9.72E−27
LOC284749 2.889682 1.42E−31
Down-regulated DEGs
SMR3B − 9.48864 3.11E−16 CSN1S1 − 8.610397883 1.76E−14
CSN1S1 − 8.13224 3.62E−15 MYOC − 5.400766258 8.60E−13
CSN3 − 7.72831 1.09E−13 MSLN − 4.537413853 3.42E−14
C4orf7 − 6.20695 1.00E−14 DMBT1 − 4.476329021 4.97E−12
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groups. PPI analysis did not find any prominent network when the two mutant and non-mutant groups were 
compared, which may be due to the limited number of identified gene sets.
Discussion
Cancer, as a multifactorial disease with complex pathological features, is influenced by genetic factors. However, 
somatic mutations are amongst the most important well-known genetic factors involved in cancer. The role of 
somatic mutations in tumor development and progression of cancer has been confirmed through advances in 
technology and increasing knowledge about mutation characteristics. In this study, we focused on the analysis of 
a gene with known roles in breast cancer, GATA38,16, using the large-scale data obtained by the TCGA  project18. 
In this cohort, the frequency of somatic mutations in GATA3 was 14.15%. As previously reported, this gene is one 
of the three genes representing more than 10% somatic mutations in all breast cancer  patients23. The analysis of 
clinical factors in relationship with the GATA3 somatic mutations reported in TCGA-BRCA project revealed that 
GATA3 mutations were associated with several clinical features and pathological subtypes of breast cancer. Also, 
differential gene expression analysis has identified different patterns of expression in normal samples, GATA3 
Figure2.  Venn diagram indicating differentially expressed genes overlapping between the samples in (A) the 
entire patient and (B) ER-positive subgroup. Blue: GATA3-Mutant versus Normal; Yellow: GATA3-Non-mutant 
versus Normal; Green: GATA3-Mutant versus Non-mutant.
Figure 3.  PPI network of breast cancer differentially expressed genes (DEGs) between normal and GATA3 
mutant samples in (A) the entire patient and (B) ER-positive subgroup. The node size is proportional to the 
degree value as the bigger size means the larger degree value. The color of the node is related to the expression of 
genes: up regulated genes are shown in Red and down regulated genes are shown in Blue.
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mutant and non-mutant tumor tissues in the entire cohort as well as in the ER-positive cases. Furthermore, our 
results also showed three pathways were significantly different between GATA3 mutant and non-mutant tumors.
Our results suggested that patients with GATA3 mutant tumors were significantly younger than those patients 
without GATA3 mutations. A previous report has indicated that younger luminal B cases had GATA3 mutations 
more frequently than older  patients24. This finding has also been validated in metastatic breast cancer  patients27. 
Since ER-positive younger patients indicated poorer  prognosis28, a higher rate of GATA3 mutations may have 
clinical importance.
Our results suggested the importance of GATA3 in tumor size in the TCGA dataset. It has been previously 
reported that mutational load is correlated with the size of tumor in breast cancer  patients29. Therefore, it is 
expected to observe a higher rate of GATA3 mutation in larger tumors. Furthermore, a higher rate of rare types 
of tumor (Mixed Histology, Mucinous Carcinoma and Medullary Carcinoma) was observed in association with 
GATA3 mutations (Table 1). Conversely, after adjustment and also in the ER-positive group, we found a significant 
difference in mutation status between ILC and IDC, but not in rare types of breast cancer (Table 2). These results 
may be affected by the small number of rare types in comparison with ductal carcinoma of the breast. However, 
this may highlight the impact of mutations on different features of breast tumors (Table 2). In addition, the results 
of our analysis showed ER-positive tumors harbored almost all GATA3 somatic mutations detected in the patient 
cohort. This finding confirms previous reports showing an association of GATA3 with ER-positive status and 
luminal differentiation, which may reflect its role in response to  chemotherapy30. Also, a study has shown that 
GATA3 up-regulates and stabilizes ER mRNA  transcription31. In contrast, GATA3 expression is down-regulated 
by progestin-induced PR  activation32. It may explain the association of GATA3 mutations with the luminal type 
of breast cancer as a hormone receptor-positive type.
As the two aspects of GATA3 have been studied, i.e. a difference in expression between mutant and non-
mutant or normal tissues and the impact of its mutations on tumor properties, it can be postulated that in 
agreement with previous studies, our data support the higher level of expression in tumor tissues than nor-
mal  samples16,33 and the lack of importance of GATA3 somatic mutations as an independent factor in patient 
 survival11,34. However, non-mutant samples showed better survival than others in ER-positive patients. META-
BRIC data indicated the prognostic value of GATA3 X308_Splice mutation, as the mutant samples had better 
survival than wild-type ones both in all patients and ER-positive  patients35. On the other hand, in samples 
representing a high expression of GATA3, mutant patients had longer survival than wild-types, and mutations in 
the second GATA3 zinc-finger (ZnFn2) was associated with lower survival time than other  mutations36. Another 
study has also reported that a significant association of GATA3 mutations with hormone receptor-positive situ-
ation may reflect the better prognosis of the  disease17. All of these different findings suggest the importance of 
mutation type and co-consideration of other related factors in the association of GATA3 somatic mutation with 
overall survival. However, different factors including the number of mutant samples and the study settings may 
cause this variation. We acknowledge such variation in these findings can make it more difficult to come to a 
straightforward conclusion. Regarding to the higher level of expression in tumor samples (GATA3 mutant and 
non-mutant) than normal ones, a meta-analysis study confirmed the relation between GATA3 overexpression 
and favorable phenotypes including ER-positive  status14. On the other hand, a cell line study indicated the 
active GATA3 transcription factors cause proliferative phenotypes and promote the growth of ER-positive breast 
cancer cell  lines37. In addition to the impact of the mutation on expression level, somatic mutations may affect 
the binding site and influence the rate of downstream genes expression and result in a changed transcriptional 
 network36,38. Furthermore, it has been observed that higher rate of GATA3 mutations in ER-positive patients may 
lead to resistance to endocrine  therapy27. Therefore, all of these findings indicate diverse activities of GATA3 
Figure 4.  PPI network of breast cancer differentially expressed genes DEGs between normal and GATA3-non-
mutant in (A) the entire patient and (B) ER-positive subgroup. The node size is proportional to the degree value 
as the bigger size means the larger degree value. The color of the node is related to the expression of genes: up 
regulated genes are shown in Red and down regulated genes are shown in Blue.
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protein which affect the luminal breast epithelial cells via different pathways can neutralize the impact of this 
gene on the prognosis of the disease.
MYH2, as a down-regulated gene in GATA3-mutant and non-mutant samples, encodes an Actin-based motor 
protein with the skeletal muscle contraction activity. According to the Human Protein  Atlas18, MYH2 protein was 
not detected in breast tissues, however, low amount of RNA has been  observed39. Since GATA3 mutants compared 
with non-mutant tumor samples did not indicate any difference in expression of MYH2, its lower expression in 
tumor samples may be resulted due to the tumor environment. Similar to MYH2, CKM (Muscle type of CK) is 
down-regulated in tumor (GATA3 mutant and non-mutant) tissues. Expression of this gene in mRNA level has 
previously been shown in breast  samples39. Furthermore, a decreased level of serum CK has been specified in 
breast cancer  patients40. Moreover, SMR3B gene (submaxillary gland androgen-regulated protein 3B) was iden-
tified to have differential expression between GATA3 mutant and non-mutant tumor tissues as mutant samples 
indicate a lower level of expression. Previously, it has been predicted SMR3B has GATA3 transcription factor 
binding site  motif41 and is expressed more in triple-negative breast cancer patients with poor prognosis compared 
to the low-risk  patients42. As GATA3 protein has a role in expression regulation, lower level of SMR3B expres-
sion in tumor carrying GATA3 mutations can be explained by this fact. CSN1S1 (Casein Alpha S1), is another 
top down-regulated gene in GATA3 mutant samples compared to non-mutants in the ER-positive subgroup. 
Its RNA expression has been identified in breast tissue, however, the protein has only been detected in lactat-
ing breast. Because of significantly different protein expression in benign prostate hyperplasia compared with 
normal and tumor prostate tissues, CSN1S1 has been reported as a potential biomarker for early identification 
of benign prostate hyperplasia  patients43. Moreover, CSN1S1 has identified as a tumor suppressor that controls 
breast tumor growth and  metastasis44. According to our finding, GATA3-mutants had larger tumor size that it 
may be due to the down-regulation of CSN1S1.
We found MUC2 over-expression in GATA3-mutant tumor than normal samples. MUC2 is up-regulated in 
mucinous  carcinomas45, and have higher expression in invasive breast tumors than adjacent normal tissues. A 
significantly higher level of serum MUC2 has also been found in breast cancer patients compared with healthy 
 people46. Furthermore, as a prognostic effector, MUC2 protein is associated with shorter disease-free  survival47. 
Evaluation of a cell line with the limited expression of MUC2 indicated a decreased rate of proliferation and better 
response to chemotherapy by efficiently induced  apoptosis48. These findings confirmed the potential prominent 
role of MUC2 expression as the prognostic marker in breast cancer. However, the relationship between GATA3 
and MUC2 remains to be evaluated. Another up-regulated gene, S100A15, is a calcium-binding protein with 
higher expression in non-mutant tumors than normal ones. While there is evidence which indicates elevated 
S100A15 transcripts in ER/PR negative breast  cancers49, the association of this gene with breast cancer prognosis 
has not been  confirmed50. In the ER-positive subgroup, CST5 (Cystatin D), was the first top differentially up-
regulated gene between non-mutants and normal. This gene has been down-regulated in colon  cancer51, and its 
induction by calcitriol can also prevent the breast cancer cells  growth52. The mutant and non-mutant comparison 
showed Aldolase B (ALDOB), a glycolytic enzyme, to be up-regulated in GATA3 mutant samples. However, 
tumor samples did not show differential expression in comparison with normal ones. Previous studies indicated 
a decreased level of ALDOB in several  cancers53,54. Therefore, the higher expression of ALDOB in GATA3 mutant 
breast cancer tumors may be caused by involved common regulatory pathways that need to be confirmed by 
functional and gene–gene interaction analyses. Furthermore, according to the Venn diagram, 75 genes in the 
entire patient group and 46 in ER-positive subgroup, were differentially expressed between GATA3-mutant and 
non-mutant tumors that may indicate the impact of GATA3 in the expression profile of the tumor cells.
Considering the differently expressed pathways, previously indicated to be associated with breast cancer, 
protein digestion and absorption pathway was different between all  categories55. Other pathways were specifi-
cally different between mutant and non-mutant tumors. Wnt/β-catenin signaling pathway is a modulating fac-
tor of mammary gland morphogenesis and cell  properties20 and mediates the increase of GATA3  expression21. 
Consistent with our finding, a previous study indicated WNT/β-catenin signaling as an enriched gene set in 
GATA3 X308_Splice mutant breast  tumor35. Cell adhesion molecules (CAMs) was another different gene set 
between tumor samples. The role of this pathway has been recognized in the carcinogenesis and metastasis 
of breast cancer. Therefore, evaluation of the involved genes can be diagnostic, prognostic and therapeutic 
 targets22,56. Besides, the regulatory role of GATA3 in adhesion molecules expression has been identified in cell 
culture  analysis57. Hence, expression variation of these genes can happen in association with GATA3 situation 
induced by mutations. These findings may reflect the interactions between GATA3 and genes involved in WNT 
and cell adhesion molecules pathways in the pathogenesis of breast cancer. Furthermore, we found that systemic 
lupus (SLE) erythematosus pathway is differentially expressed between ER-positive breast tumor and normal 
tissues. It has been shown that SLE is influenced by estrogen-estrogen receptor-mediated signaling through 
the modulation of cytokine  production58. There are also reports indicating a lower rate of hormone-dependent 
cancers in SLE patients although they may tend for a higher incidence of triple-negative breast cancer compared 
to general  population59. As the main finding of the protein–protein interaction analysis, IL6 was identified to 
be an important hub node in the comparison between tumor and normal samples. In line with our results indi-
cating the contribution of this gene in different pathways, IL6 overexpression has been previously described in 
breast  cancer60. Many cellular functions including oncogenesis are influenced by  IL661. These findings suggest 
the crucial role of IL6 in the pathogenesis of breast cancer and the importance of targeting this gene in the treat-
ment of the disease.
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Conclusion
In conclusion, our results suggest that GATA3 mutation status is associated with a number of clinicopathological 
features, as well as with overall survival time only in ER-positive breast cancer. Our results also indicate a pos-
sible common biological process involving GATA3 mutations and ER/PR status, which needs to be confirmed 
by functional analyses. The GATA3 mutations may influence the expression profile of the tumor cells via impact 
on expression and activity rate of the GATA3 gene. These findings should also be confirmed using gene–gene 
interaction analyses and homogenous samples.
Methods
Patients and data files. The study population has consisted of female breast cancer patients in the TCGA-
BRCA cohort. Information on the GATA3 mutations in the tumors was retrieved from https ://porta l.gdc.cance 
r.gov. This information was available for 975 of the patients. The tumor mRNA expression data (level 3 data; 
including raw count data) was extracted from Illuminahiseq_rnaseqV2-exon_quantification (MD5) data file at 
https ://gdac.broad insti tute.org/. This data was available for 771 tumor (671 non-mutant and 100 mutant) and 99 
normal tissues of the patients. Demographic and clinical data were obtained from the file rendered by the Legacy 
Archive of the GDC portal at https ://porta l.gdc.cance r.gov/legac y-archi ve/files /735bc 5ff-86d1-421a-8693-6e6f9 
20555 63. Categorization of the study population was performed according to standard  protocols62–68. All analy-
ses were also replicated in ER-positive samples including 482 non-mutant and 92 mutant tumor tissues.
Computational analysis of expression profile. The edgeR program (http://bioco nduct or.org/packa 
ges/relea se/bioc/html/edgeR .html) is a Bioconductor software package for examining the differential expression 
of replicated count data using an over-dispersed Poisson model and Empirical Bayes methods to account for 
both biological and technical variability and moderate the degree of over-dispersion across  transcripts69. This 
program was used to determine the DEGs in the normal tissues when compared to the tumors (GATA3 mutant 
and non-mutant). The probabilistic methods were used by edgeR to evaluate the differential expression. The 
affected genes determined based on a false discovery rate (FDR) < 0.05 and a log Fold change (FC) > 1.
Functional annotation of differentially expressed genes (DEGs). The proteins encoded by DEGs 
were analyzed, and annotated using Metascape, “A Gene Annotation and Analysis Resource”, which can be used 
to analyze multi-platform OMICs data (http://metas cape.org/gp/index .html), DAVID “Database for Annota-
tion, Visualization and Integrated Discovery” (https ://david .ncifc rf.gov/)70–72 to test for gene set enrichment 
analysis, Gene Ontology (GO) terms and pathways. According to the database, DAVID pathways output is based 
on KEGG (Kyoto Encyclopedia of Genes and Genomes). Only terms with modified Fisher Exact p value ≤ 0.05 
were considered significant. Metascape is a web-based portal, and is useful for functional annotations of  genes73.
Protein–protein interaction (PPI) network. DEGs (corrected p values ≤ 0.05) were imported to the 
search tool of STRING (v10.0, http://strin g-db.org/) for the retrieval of interacting genes/proteins by selecting 
Homo sapiens as the organism. STRING can identify a network of close interactions among this set of genes 
based on information on experimental as well as predicted protein interactions. The three methods including 
degree centrality, betweenness centrality, and closeness centrality were used to calculate the topology scores of 
nodes in the PPI network using the  CytoNCA74.
Statistical analysis. Demographic and clinical/molecular data that were examined during statistical analy-
ses are shown in the supplementary information file, Table S1. Comparison between variables between the two 
groups (mutant vs. non-mutant) was examined using Pearson’s Chi-squared test for categorical variables and 
independent sample t test for continuous variables. Univariate logistic regression analysis was used to exam-
ine the associations of GATA3 somatic mutation status with different variables, and the odds ratios (OR) and 
95% confidence intervals (CIs) were presented. Multivariate logistic regression analysis was used to assess the 
variables that were independently predictive of the GATA3 mutation status. For this purpose, covariates with p 
values ≤ 0.05 in the univariate analysis were entered into a multivariable model, excluding the rare variables (ER 
status and hormone receptor status). In addition, menopause status and age at diagnosis were highly associated, 
thus, menopausal status (which had more missing data than the age at diagnosis) was excluded from the multi-
variable model.
Overall survival (OS) time is defined as the time from diagnosis till the time of death or last contact. Associa-
tions between variables and OS were examined using the Kaplan–Meier plots/Log-rank test and Cox proportional 
hazards regression methods. Results of the univariate Cox regression analysis was used to select the variables 
to be entered into the multivariable Cox regression models. For this purpose, covariates with p values less than 
0.05 in the univariate analysis were entered into a covariate selection method (Backward-LR), excluding the 
rare variables, such as metastasis status (pM) and history of neoadjuvant therapy, and highly correlated vari-
ables. Highly correlated variables included menopausal status (excluded) and age at diagnosis, tumor size (pT) 
(excluded) and stage, and lymph node ratio (excluded) and lymph node status (pN). As a result, age, stage, and 
radiation therapy status were selected for the analysis of the entire cohort. Association of the GATA3 mutation 
status with OS was then examined in a multivariable Cox model after adjusting for these clinical factors. Similar 
to this process, OS analysis was done for the ER-positive subgroup. After excluding the rare variables, such as 
metastasis status and history of neoadjuvant therapy, and highly correlated variables including menopausal 
status, tumor size and lymph node ratio, the variables including age, stage, and lymph node status were selected 
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for the assessment of the GATA3 mutations’ association with OS in a multivariable Cox model. The hazard rate 
ratio (HR) and 95% CIs were calculated by the Cox models.
A p value < 0.05 was considered significant. All statistical analyses were performed using SPSS 16.0 (IBM, 
USA).
Ethical approval. This article does not contain any studies with human participants performed by any of 
the authors.
 Data availability
The Data belongs to TCGA Research Network and is available in https ://www.cance r.gov/tcga.
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